<DOC>
	<DOCNO>NCT02735863</DOCNO>
	<brief_summary>This study placebo-controlled study aim assess safety ABX464 administer 50 mg 150 mg o.d . versus placebo HIV infect patient treat darunavir + ritonavir ( DRV/RTV ) darunavir + cobicistat ( DRV/COBI ) .</brief_summary>
	<brief_title>ABX464 Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment</brief_title>
	<detailed_description>This study placebo-controlled study aim assess safety ABX464 administer 50 mg o.d . 150 mg versus placebo HIV infect patient treat darunavir + ritonavir ( DRV/RTV ) darunavir + cobicistat ( DRV/COBI ) . Eligible patient treat darunavir + ritonavir darunavir + cobicistat monotherapy least 8 week prior baseline . Patients fully suppress ( &lt; 50 copies/mL ) least last 6 month prior enrolment . Upon screen visit , eligible patient continue DRV/RTV DRV/COBI single regimen give respectively 800 mg darunavir 100 mg ritonavir 150 mg cobicistat day food morning . At Day 0 , study drug ( ABX464 match placebo ) add top background therapy next 28 day . ABX464 match placebo give day 50 mg 150 mg. At day 29 , DRV/RTV DRV/COBI ABX464 match placebo ( i.e . treatment ) stop . The viral load monitor twice week first three week weekly next week . In case Viral Rebound ( VR ; define ) , ART resume . A 3:1 randomization ratio apply meaning , per treatment block , 3 patient receive ABX464 top DRV/RTV DRV/COBI 1 patient receive placebo top DRV/RTV DRV/COBI . Dose limit toxicity ( DLT ) define grade 3 high adverse event define `` Division AIDS table grade severity adult pediatric adverse event '' ( include signs/symptoms , lab toxicity and/or clinical event ) consider Data Safety Monitoring Board probably definitely related study treatment . If 2 DLTs occur treatment period first four treated patient , enrolment additional patient stop . In addition , case life threaten ( grade 4 ) adverse reaction enrolment treatment ongoing patient immediately discontinue . In case , enrolment resume upon decision sponsor Data Safety Monitoring Board conclude causality event unrelated unlikely related study treatment . Thorough pharmacokinetics analysis perform characterize potential drug-drug interaction ABX464 DRV/RTV-COBI .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Patients infected HIV ; Patients HIV plasma viral load ≤ 50 copy mL1 6 month prior screen maximum 2 blip period ; Patients treat DRV/RTV DRV/COBI monotherapy least 8 week prior baseline ; Patients ' HIV plasma viral load ≤100,000 copy mL1 time ( apart primary infection record ) ; Patients ' CD4+ T cell count ≥ 250 cell per mm3 time since diagnosis ; Patients CD4+ T cell count ≥ 600 cell per mm3 screening ; Man woman age 1865 year ; Patient display HIV protease inhibitor resistance mutation list current version HIV drug resistance database ( Stanford University ) ; Patient previously viral load ≥ 500 copy mL1 confirm second measure since initiation current ART ; History AIDSdefining clinical illness ; Concomitant AIDSrelated opportunistic infection ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>